Cargando…

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview

Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologous hematopoietic stem cell transplant (auto-HSCT) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagnew, Alemnew F., Vink, Peter, Drame, Mamadou, Willer, David O., Salaun, Bruno, Schuind, Anne E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827627/
https://www.ncbi.nlm.nih.gov/pubmed/34190658
http://dx.doi.org/10.1080/21645515.2021.1930846
_version_ 1784647674349223936
author Dagnew, Alemnew F.
Vink, Peter
Drame, Mamadou
Willer, David O.
Salaun, Bruno
Schuind, Anne E.
author_facet Dagnew, Alemnew F.
Vink, Peter
Drame, Mamadou
Willer, David O.
Salaun, Bruno
Schuind, Anne E.
author_sort Dagnew, Alemnew F.
collection PubMed
description Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and hematologic malignancy (HM) patients. We review immune responses to RZV in 5 adult IC populations, 4 of which were receiving multiple, concomitant immunosuppressive medications: auto-HSCT and renal transplant recipients, HM and solid tumor patients, and human immunodeficiency virus-infected adults. Although administered in most cases when immunosuppression was near its maximum, including concomitantly with chemotherapy cycles, RZV induced robust and persistent humoral and, more importantly, CMI responses in all 5 IC populations. Based on the overall clinical data generated in older adults and IC individuals, RZV is expected to provide benefit in a broad adult population at risk for HZ.
format Online
Article
Text
id pubmed-8827627
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88276272022-02-10 Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview Dagnew, Alemnew F. Vink, Peter Drame, Mamadou Willer, David O. Salaun, Bruno Schuind, Anne E. Hum Vaccin Immunother Mini-Review Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and hematologic malignancy (HM) patients. We review immune responses to RZV in 5 adult IC populations, 4 of which were receiving multiple, concomitant immunosuppressive medications: auto-HSCT and renal transplant recipients, HM and solid tumor patients, and human immunodeficiency virus-infected adults. Although administered in most cases when immunosuppression was near its maximum, including concomitantly with chemotherapy cycles, RZV induced robust and persistent humoral and, more importantly, CMI responses in all 5 IC populations. Based on the overall clinical data generated in older adults and IC individuals, RZV is expected to provide benefit in a broad adult population at risk for HZ. Taylor & Francis 2021-06-30 /pmc/articles/PMC8827627/ /pubmed/34190658 http://dx.doi.org/10.1080/21645515.2021.1930846 Text en © 2021 GlaxoSmithKline Biologicals S.A. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mini-Review
Dagnew, Alemnew F.
Vink, Peter
Drame, Mamadou
Willer, David O.
Salaun, Bruno
Schuind, Anne E.
Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
title Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
title_full Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
title_fullStr Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
title_full_unstemmed Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
title_short Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
title_sort immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827627/
https://www.ncbi.nlm.nih.gov/pubmed/34190658
http://dx.doi.org/10.1080/21645515.2021.1930846
work_keys_str_mv AT dagnewalemnewf immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview
AT vinkpeter immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview
AT dramemamadou immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview
AT willerdavido immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview
AT salaunbruno immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview
AT schuindannee immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview